Business
Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701
Preclinical data highlight improved potency vs. asciminib across multiple clinically relevant variants of BCR-ABL including difficult-to-treat resistance
About this update from Terns Pharmaceuticals, Inc.
[{"type":"text","content":"Preclinical data highlight improved potency vs. asciminib across multiple clinically relevant variants of BCR-ABL including difficult-to-treat resistance mutations Early dose-escalation data from Phase 1 CARDINAL study of TERN-701 in CML patients showed compelling molecular responses in patients with heavily pre-treated CML, including deepening responses in patients with poor response to asciminib Additional safety and efficacy data from CARDINAL, including 6-month major molecular response (MMR) rates expected 4Q 2025 FOSTER CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that preclinical data supporting the potential of TERN-701 as a treatment for chronic myeloid leukemia (CML) will be highlighted in an oral presentation at the 30th European Hematology Association Congress (EHA25) taking place from June 12-15, 2025 in Milan, Italy. TERN-701 is an investigational next-generation allosteric BCR-ABL inhibitor specifically targeting the ABL myristoyl pocket. The preclinical data to be presented highlight the potency of TERN-701 on more than 20 clinically relevant resistance mutations in the active-site, P-loop, and allosteric regions of the BCR-ABL oncoprotein, and provide additional data characterizing the drug-like properties of TERN-701 and supporting the potential to provide meaningful clinical benefits over existing therapies. “We are delighted our abstract has been selected for oral presentation at EHA25. These preclinical data provide further mechanistic insights into the clinical responses we have seen in our ongoing phase 1 study including deepening responses after suboptimal responses to asciminib and other TKIs,” stated Emil Kuriakose, M.D., chief medical officer of Terns Pharmaceuticals. “We are especially encouraged by the greater potency of TERN-701 compared to asciminib against several resistance mutations in the active-site and allosteric domains, implying potential for improved clinical responses with TERN-701 in patients with these mutations and supporting the potential for TERN-701 to be a best in class therapy for CML patients in all lines of therapy.” Details of the...